Lilly to Withdraw Lartruvo from Market, Assist Patients
Lilly last month detailed plans to invest $850 million into its U.S. operations this year.
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowIndianapolis-based Eli Lilly and Co. (NYSE: LLY) has announced that it is working to facilitate the withdrawal of its advanced soft tissue sarcoma treatment, Lartruvo, from the market. The move follows a clinical trial in which the medication did not improve survival for patients.
Lilly says it is working to ensure that patients who are currently receiving Lartruvo may, in consultation with their physician, continue their course of therapy if they have been informed of the risks of Lartruvo and the results of the study and wish to continue, subject to local laws and regulations.
The company says it will also establish a program to support patients who are currently receiving Lartruvo to allow them to continue treatment with limited interruption after Lartruvo is withdrawn from the market, subject to local laws and regulations. The program details will be distributed to medical professionals in the next few weeks.
"Lilly wants to ensure that patients and physicians feel supported during this important time," said Anne White, president, Lilly Oncology, in a news release. "Advanced soft tissue sarcoma is a rare and difficult-to-treat cancer. Establishing this program will give patients who are currently taking Lartruvo the opportunity to continue their treatment program uninterrupted."
No new patients should receive Lartruvo outside of participation in ongoing clinical trials.